NCT06883747View on ClinicalTrials.gov

Clinical Trial of BMS-986504 in Recurrent GBM Patients

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

September 28, 2026

Study Completion Date

September 28, 2027

Conditions

Glioblastoma WHO Grade IV

Interventions

DRUG

BMS-986504

MTA cooperative PRMT5 inhibitor

Trial Locations (1)

85013

RECRUITING

St. Joseph's Hospital and Medical Center, Phoenix

All Listed Sponsors

lead

Nader Sanai

OTHER